Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metablok - Arch Biopartners

Next Previous
Drug Profile

Metablok - Arch Biopartners

Alternative Names: LSALT peptide; MetaBlok

Latest Information Update: 29 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arch Biopartners; University of Calgary
  • Developer Arch Biopartners; Sunnybrook Health Sciences Centre; University of Calgary
  • Class Peptides; Small molecules
  • Mechanism of Action Dipeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute kidney injury; COVID 2019 infections; SARS-CoV-2 acute respiratory disease
  • No development reported Cancer metastases; Sepsis

Most Recent Events

  • 22 Apr 2025 University Health Network (UHN) Research Ethics Board approves Toronto General Hospital to participate in the CS-AKI Phase II trial
  • 15 Jan 2025 9433517: Updated KDM and added HE for the same (update discussed with SME (Akash)
  • 08 Jan 2025 University Health Network Research Ethics Board through the Clinical Trials Ontario Streamlined Research Ethics Review System grants provincial ethics approval for the Phase II trial for Metablok in Acute kidney injury

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top